MX367657B - Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. - Google Patents
Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.Info
- Publication number
- MX367657B MX367657B MX2016002289A MX2016002289A MX367657B MX 367657 B MX367657 B MX 367657B MX 2016002289 A MX2016002289 A MX 2016002289A MX 2016002289 A MX2016002289 A MX 2016002289A MX 367657 B MX367657 B MX 367657B
- Authority
- MX
- Mexico
- Prior art keywords
- acute
- treatment
- diaminopyrimidine
- sub
- chronic cough
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención pertenece a compuestos de diaminopirimidina que tienen actividad como antagonistas de receptores purinérgicos de P2X, y a métodos para el tratamiento de enfermedades asociadas con receptores de P2X que comprenden administrar una cantidad efectiva de un compuesto de diaminopirimidina. Más particularmente, los métodos se proporcionan para utilizar antagonistas de P2X3 y/o P2X2/3 en el tratamiento de la tos, tos crónica, una necesidad para toser durante padecimientos y trastornos respiratorios.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361869174P | 2013-08-23 | 2013-08-23 | |
PCT/US2014/052389 WO2015027212A1 (en) | 2013-08-23 | 2014-08-22 | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016002289A MX2016002289A (es) | 2016-09-06 |
MX367657B true MX367657B (es) | 2019-08-30 |
Family
ID=52480919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016002289A MX367657B (es) | 2013-08-23 | 2014-08-22 | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. |
Country Status (21)
Country | Link |
---|---|
US (3) | US9284279B2 (es) |
EP (2) | EP3865134A1 (es) |
JP (3) | JP6546592B2 (es) |
KR (1) | KR102196885B1 (es) |
CN (1) | CN105682659B (es) |
AU (1) | AU2014308606B2 (es) |
CA (1) | CA2921395C (es) |
CL (3) | CL2016000400A1 (es) |
CR (1) | CR20160093A (es) |
HK (1) | HK1222126A1 (es) |
IL (1) | IL244131B (es) |
MX (1) | MX367657B (es) |
MY (1) | MY195728A (es) |
NI (1) | NI201600029A (es) |
NZ (1) | NZ716977A (es) |
PE (1) | PE20160431A1 (es) |
PH (1) | PH12016500357A1 (es) |
RU (1) | RU2650118C2 (es) |
SG (1) | SG11201601145RA (es) |
UA (1) | UA118851C2 (es) |
WO (1) | WO2015027212A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3865134A1 (en) * | 2013-08-23 | 2021-08-18 | Afferent Pharmaceuticals Inc. | Methods of using diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases |
EP3104853B1 (en) | 2014-02-10 | 2019-10-02 | Respivant Sciences GmbH | Mast cell stabilizers treatment for systemic disorders |
HUE049323T2 (hu) | 2014-02-10 | 2020-09-28 | Respivant Sciences Gmbh | Hízósejt-stabilizálók tüdõbetegség kezelésére |
WO2017011729A1 (en) | 2015-07-16 | 2017-01-19 | Patara Pharma, LLC | Combination therapies for the treatment of lung diseases |
EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
KR20180054843A (ko) * | 2015-09-29 | 2018-05-24 | 애퍼런트 파마슈티컬스 인크. | 기침 치료에 사용하기 위한 디아미노피리미딘 p2x3 및 p2x2/3 수용체 조정제 |
US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
MA44489A (fr) | 2016-03-25 | 2019-01-30 | Afferent Pharmaceuticals Inc | Pyrimidines et variants de celles-ci, et leurs utilisations |
WO2018044942A1 (en) | 2016-08-31 | 2018-03-08 | Patara Pharma, LLC | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
WO2018067341A1 (en) | 2016-10-07 | 2018-04-12 | Patara Pharma, LLC | Cromolyn compositions for treatment of pulmonary fibrosis |
WO2018111738A1 (en) | 2016-12-15 | 2018-06-21 | Afferent Pharmaceuticals, Inc. | Substituted pyrazole-pyrimidines, variants thereof, and uses therefore |
KR102557242B1 (ko) * | 2016-12-20 | 2023-07-18 | 애퍼런트 파마슈티컬스 인크. | P2x3 길항제의 결정질 염 및 다형체 |
US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
CN108904507A (zh) * | 2018-02-11 | 2018-11-30 | 赖英杰 | P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用 |
CA3093409A1 (en) | 2018-03-15 | 2019-09-19 | Danmir Therapeutics, Llc | 3",5"-dialkoxybenzoyl-3'-amino-3'-deoxyadenosine-5'-triphosphates and pharmaceutical uses thereof |
CN112423756A (zh) * | 2018-04-23 | 2021-02-26 | 默沙东公司 | 用于合成苯氧基二氨基嘧啶化合物的新方法 |
JOP20200286A1 (ar) | 2018-05-15 | 2020-11-09 | Bayer Ag | بنزاميدات مستبدلة بـ 1 ، 3-ثيازول-2-يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية |
SG11202011018PA (en) | 2018-05-15 | 2020-12-30 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
SG11202100580UA (en) * | 2018-07-23 | 2021-02-25 | Trevi Therapeutics Inc | Treatment of chronic cough, breathlessness and dyspnea |
CA3115649A1 (en) * | 2018-10-05 | 2020-04-09 | Shionogi & Co., Ltd. | Medicament for the treatment of chronic cough |
US20220177447A1 (en) * | 2019-04-30 | 2022-06-09 | Beijing Tide Pharmaceutical Co., Ltd. | Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof |
AU2020265327A1 (en) * | 2019-04-30 | 2021-12-16 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating cough by using diaminopyrimidine compound |
US20220396561A1 (en) | 2019-09-19 | 2022-12-15 | Shionogi & Co., Ltd. | Crystal of 1,3,5-triazine derivative or solvate thereof and method for producing same |
CN111635368B (zh) * | 2020-06-12 | 2021-06-29 | 东莞市东阳光仿制药研发有限公司 | 一种胺化合物的制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005229331B2 (en) | 2004-03-05 | 2011-10-13 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as P2X3 and P2X2/3 antagonists |
CA2573565A1 (en) | 2004-07-22 | 2006-02-02 | Duska Scientific Co. | Method of diagnosing, monitoring and treating pulmonary diseases |
CA2620129C (en) | 2005-09-01 | 2014-12-23 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
JP4850911B2 (ja) | 2005-09-01 | 2012-01-11 | エフ.ホフマン−ラ ロシュ アーゲー | P2x3およびp2x2/3モジュレーターとしてのジアミノピリミジン |
SI1924264T1 (sl) | 2005-09-01 | 2013-12-31 | F. Hoffmann-La Roche Ag | Diaminopirimidini kot modulatorji p2x3 in p2x2/3 |
WO2007025898A1 (en) | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Process for synthesis of aryloxy diaminopyrimidines |
PL2343281T3 (pl) * | 2006-10-04 | 2014-08-29 | Hoffmann La Roche | Sposób syntezy pochodnych fenoksydiaminopirymidyny |
WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
WO2013118855A1 (ja) * | 2012-02-09 | 2013-08-15 | 塩野義製薬株式会社 | 複素環および炭素環誘導体 |
EP3865134A1 (en) | 2013-08-23 | 2021-08-18 | Afferent Pharmaceuticals Inc. | Methods of using diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases |
US9222282B2 (en) * | 2013-10-11 | 2015-12-29 | Nexkey, Inc. | Energy efficient multi-stable lock cylinder |
-
2014
- 2014-08-22 EP EP21159088.0A patent/EP3865134A1/en active Pending
- 2014-08-22 AU AU2014308606A patent/AU2014308606B2/en active Active
- 2014-08-22 UA UAA201601740A patent/UA118851C2/uk unknown
- 2014-08-22 NZ NZ716977A patent/NZ716977A/en unknown
- 2014-08-22 MY MYPI2016000327A patent/MY195728A/en unknown
- 2014-08-22 RU RU2016105581A patent/RU2650118C2/ru active
- 2014-08-22 EP EP14838254.2A patent/EP3035932A4/en not_active Withdrawn
- 2014-08-22 KR KR1020167007167A patent/KR102196885B1/ko active IP Right Grant
- 2014-08-22 JP JP2016536497A patent/JP6546592B2/ja active Active
- 2014-08-22 PE PE2016000285A patent/PE20160431A1/es unknown
- 2014-08-22 US US14/466,713 patent/US9284279B2/en active Active
- 2014-08-22 MX MX2016002289A patent/MX367657B/es active IP Right Grant
- 2014-08-22 CA CA2921395A patent/CA2921395C/en active Active
- 2014-08-22 CR CR20160093A patent/CR20160093A/es unknown
- 2014-08-22 SG SG11201601145RA patent/SG11201601145RA/en unknown
- 2014-08-22 CN CN201480058491.3A patent/CN105682659B/zh active Active
- 2014-08-22 WO PCT/US2014/052389 patent/WO2015027212A1/en active Application Filing
-
2016
- 2016-02-02 US US15/013,798 patent/US9724346B2/en active Active
- 2016-02-15 IL IL244131A patent/IL244131B/en active IP Right Grant
- 2016-02-22 NI NI201600029A patent/NI201600029A/es unknown
- 2016-02-22 CL CL2016000400A patent/CL2016000400A1/es unknown
- 2016-02-23 PH PH12016500357A patent/PH12016500357A1/en unknown
- 2016-08-31 HK HK16110333.7A patent/HK1222126A1/zh unknown
-
2017
- 2017-08-01 US US15/665,595 patent/US10206922B2/en active Active
-
2018
- 2018-08-08 CL CL2018002137A patent/CL2018002137A1/es unknown
- 2018-08-08 CL CL2018002138A patent/CL2018002138A1/es unknown
-
2019
- 2019-03-25 JP JP2019055849A patent/JP7210348B2/ja active Active
-
2022
- 2022-10-18 JP JP2022166618A patent/JP7423725B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016500357A1 (en) | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough | |
PH12019501448A1 (en) | Immunomodulator compounds and methods of use | |
MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
PH12016501966B1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
MX2016005560A (es) | Compuestos agonistas triples de glucagon-glp-1-gip. | |
MX2021011939A (es) | Compuestos neuroactivos y metodos de uso de los mismos. | |
BR112014020826A2 (pt) | moduladores e métodos de uso | |
MY172578A (en) | Oral dosing of glp-1 compounds | |
BR112016009889A2 (pt) | ?compostos agonistas duplos gip-glp-1 e métodos? | |
MX2015002292A (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r. | |
MY189912A (en) | Substituted xanthines and methods of use thereof | |
UA117032C2 (uk) | Селективний інгібітор фосфатидилінозитол-3-кінази-гамма | |
PH12017500710A1 (en) | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | |
MX2016006657A (es) | Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis. | |
MX371343B (es) | Moduladores del receptor x hepatico (lxr). | |
MX2016002930A (es) | Moduladores del receptor x hepatico (lxr). | |
IT201600130012A1 (it) | Composizione per uso nel trattamento di disturbi dell'apparato uro-genitale | |
BR112016019893A2 (pt) | composições de glicoproteína sialilada e seus usos | |
PH12015502820A1 (en) | Nanoparticulate formulation comprising a trpa1 antagonist | |
NZ724799A (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders | |
ES2586805T3 (es) | Análogos de péptidos para tratar enfermedades y trastornos | |
JO3621B1 (ar) | مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll | |
MX2019009243A (es) | Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |